Hyo-Cheol Kim
Clinical Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (17)
Supplementary Figure S4. Kaplan–Meier estimates of time to progression and overall survival according to etiology in the intent-to-treat population. (A) Time to progression. (B) Overall survival. (C) Progression-free survival.
Year:
2025
Supplementary Figure S2. Kaplan–Meier estimates of time to progression and overall survival according to BCLC stage in the intent-to-treat population. (A) Time to progression. (B) Overall survival. (C) Progression-free survival.
Year:
2025
Supplementary Figure S1. Kaplan–Meier estimates of time to progression and overall survival in the per-protocol population. (A) Time to progression. (B) Overall survival. (C) Progression-free survival.
Year:
2025
Supplementary Figure S3. Kaplan–Meier estimates of time to progression and overall survival according to BCLC stage in the per-protocol population. (A) Time to progression. (B) Overall survival. (C) Progression-free survival.
Year:
2025
Supplementary Figure S5. Kaplan–Meier estimates of time to progression and overall survival according to etiology in the per-protocol population. (A) Time to progression. (B) Overall survival. (C) Progression-free survival.
Year:
2025
Purpose: Synergistic effect of radiotherapy and immunotherapy for the treatment of hepatocellular carcinoma (HCC) has been reported. This phase I/IIa pilot trial evaluated preliminary efficacy and safety of combination of radioembolization with yttrium-90 microspheres (Y90-radioembolization) and durvalumab in patients with locally advanced unresectable HCC. Patients and Methods: Patients with Child-Pugh score ≤ 7 and locally advanced HCC, defined as Barcelona Clinic Liver Cancer (BCLC) stage B HCC or BCLC-C disease without extrahepatic metastases, received Y90-radioembolization followed by intravenous durvalumab 1,500 mg 7 to 14 days after Y90-radioembolization and every 4 weeks thereafter. Primary endpoint was time to progression (TTP) assessed by modified RECIST (mRECIST). Secondary endpoints included overall survival (OS), progression-free survival (PFS), objective response rate (ORR) determined by mRECIST, and safety. Results: All 24 patients enrolled received Y90-radioembolization and 23 received at least one dose of durvalumab. Median follow-up duration was 19.0 months (range, 2.2–24.2). Median TTP was 15.2 months [95% confidence interval (CI), 6.1–not estimated]. Median OS was not reached and 18-month OS rate was 58.3% (95% CI, 36.4–75.0). Median PFS was 6.9 months (95% CI, 5.4–15.2). Seven (29.2%) patients had a complete response and 13 (54.2%) had a partial response; ORR was 83.3% (95% CI, 62.6–95.3). Eleven (47.8%) patients experienced any-grade treatment-related adverse events. Two (8.7%) patients had grade 3 treatment-related adverse events (neutropenia and fever). None experienced any treatment-related serious adverse events. Conclusions: In patients with locally advanced unresectable HCC, the combination of Y90-radioembolization and durvalumab demonstrated promising efficacy and safety, warranting further evaluation in large-scale controlled trials.
Year:
2025
Supplementary Figure S3. Kaplan–Meier estimates of time to progression and overall survival according to BCLC stage in the per-protocol population. (A) Time to progression. (B) Overall survival. (C) Progression-free survival.
Year:
2024
Supplementary Figure S1. Kaplan–Meier estimates of time to progression and overall survival in the per-protocol population. (A) Time to progression. (B) Overall survival. (C) Progression-free survival.
Year:
2024
Supplementary Figure S4. Kaplan–Meier estimates of time to progression and overall survival according to etiology in the intent-to-treat population. (A) Time to progression. (B) Overall survival. (C) Progression-free survival.
Year:
2024
Supplementary Figure S2. Kaplan–Meier estimates of time to progression and overall survival according to BCLC stage in the intent-to-treat population. (A) Time to progression. (B) Overall survival. (C) Progression-free survival.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (6)
Eun Ju Cho
Seoul National University
Yoon Jun Kim
Professor
Seoul National University College of Medicine
Jin Chun Paeng
Associate Professor
Seoul National University Hospital
Jung‐Hwan Yoon
Professor
Seoul National University Hospital
Jeong-Hoon Lee
Professor
Seoul National University Hospital
Yun Bin Lee
Associate Professor
Seoul National University Hospital
Make your next move.
Prepare your application
Review drafts before you send them.